Edition:
India

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

80.78USD
12 Dec 2017
Change (% chg)

$-1.24 (-1.51%)
Prev Close
$82.02
Open
$82.83
Day's High
$84.44
Day's Low
$79.02
Volume
39,239
Avg. Vol
34,742
52-wk High
$100.99
52-wk Low
$13.11

Chart for

About

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product,... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $586.42
Shares Outstanding(Mil.): 12.50
Dividend: --
Yield (%): --

Financials

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL

06 Dec 2017

BRIEF-Madrigal Pharmaceuticals reports Q3 loss per share of $0.68

* Madrigal Pharmaceuticals reports 2017 third quarter financial results

09 Nov 2017

BRIEF-Madrigal Pharmaceuticals announces outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196

* Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia

19 Sep 2017

BRIEF-Madrigal Pharmaceuticals reports qtrly loss per share $0.69‍​

* Madrigal Pharmaceuticals reports 2017 second quarter financial results

10 Aug 2017

BRIEF-Madrigal Pharma completes Phase 2 enrollment for study on treatment of NASH

* Completes enrollment in Phase 2 proof-of-concept study with MGL-3196 for treatment of NASH

01 Aug 2017

BRIEF-Madrigal Pharma announces $35 million private placement offering

* Madrigal pharmaceuticals announces $35 million private placement offering

21 Jun 2017

Earnings vs. Estimates